# Amphetamine Toxicity

Amphetamine toxicity is a clinical sympathomimetic emergency requiring rapid recognition of hyperthermia, agitation, seizures, cardiovascular ischemia or dysrhythmia, rhabdomyolysis, and co-ingestion, followed by targeted monitoring and escalation for organ-specific complications.

**Clinical question:** How should clinicians identify immediate threats, investigate complications, and direct monitoring in suspected amphetamine toxicity?

Updated: 2026-09-15T23:55:57.802995+00:00

## What matters in practice
- Treat suspected amphetamine toxicity as a clinical diagnosis while evaluating for dangerous mimics, co-ingestion, and organ-specific injury; toxicology testing supports exposure assessment but does not replace bedside assessment. [7][9][21]
- A temperature greater than 104°F signals life-threatening toxicity with risk of rhabdomyolysis and multiorgan complications. [1][3][5][17]
- Obtain an ECG and use cardiac biomarkers when chest pain, ischemic ECG changes, dysrhythmia, hemodynamic instability, or cardiopulmonary symptoms raise concern for myocardial injury. [7][9][21]
- Check CK, chemistry studies, and urinalysis when hyperthermia, seizure, prolonged agitation, rigidity, or dark urine suggests rhabdomyolysis or acute kidney injury. [21][22]
- Amphetamine-related cardiovascular emergencies include tachyarrhythmia, hypertension or hypotension, vasospasm, myocardial infarction, aortic dissection, cardiomyopathy, and circulatory collapse. [1][3][5][17]

## Identify patients needing resuscitation and monitored care

Prioritize physiologic threats over confirmation of the exposure.

Place patients with altered mental status, severe agitation, hyperthermia, seizure, chest pain, dyspnea, syncope, marked blood-pressure abnormality, or suspected mixed ingestion in a monitored setting. Amphetamine overdose can produce tachyarrhythmias, hypertension or hypotension, circulatory collapse, vasospasm, myocardial infarction, aortic dissection, Takotsubo cardiomyopathy, seizures, stroke, coma, and rhabdomyolysis. [1][3][5]

Measure core temperature promptly when feasible in a patient with agitation, diaphoresis, rigidity, seizure, or depressed consciousness. Temperature greater than 104°F is identified in FDA labeling as life-threatening hyperthermia and should trigger immediate active cooling and evaluation for rhabdomyolysis and end-organ injury. [1][3][5][17]

Assess airway protection, ventilation, circulation, glucose, mental status, and trauma at presentation. Do not attribute coma, focal neurologic deficit, persistent chest pain, shock, or a focal infectious syndrome solely to stimulant exposure; amphetamine-associated cerebral vascular accidents, cardiac ischemia, endocarditis in people injecting drugs, and bloodstream or bone/joint infections require disease-specific evaluation. [1][3][5][21][22]
- Call Poison Help at 1-800-222-1222 or consult a medical toxicologist for individualized overdose management, particularly with severe toxicity, prolonged symptoms, uncertain formulation, or suspected polysubstance exposure. [1][3][4][5][6]
- Do not rely on dialysis for amphetamine elimination: d-amphetamine is not dialyzable. [1][3][5]
- Avoid urine acidification as an elimination strategy; although it may increase excretion of some amphetamine derivatives, it may worsen renal toxicity when rhabdomyolysis is present. [17]

*Immediate findings that should redirect care toward a specific complication. [1][3][5][17][21][22]*

| Presentation | Immediate concern | Next diagnostic action |
| --- | --- | --- |
| Core temperature >104°F | Life-threatening hyperthermia; rhabdomyolysis and organ injury | Initiate active cooling; obtain CK, chemistry studies, and urinalysis. [1][3][5][21] |
| Chest pain, dyspnea, syncope, abnormal rhythm, or unstable blood pressure | Vasospasm, myocardial infarction, dysrhythmia, cardiomyopathy, aortic dissection, or circulatory collapse | Obtain ECG; add cardiac biomarkers and cardiopulmonary imaging based on presentation. [1][3][5][7][9][21] |
| Seizure, coma, focal deficit, or persistent delirium | Seizure-related injury, stroke, intracranial process, or co-ingestion | Check glucose and pursue neurologic evaluation rather than assuming uncomplicated intoxication. [1][3][5] |
| Hyperthermia, prolonged agitation, seizure, muscle pain, weakness, or dark urine | Rhabdomyolysis and acute kidney injury | Obtain CK, comprehensive chemistry panel, and urinalysis; trend abnormalities according to severity. [1][3][5][21] |

## Use targeted testing to detect toxicity complications

Testing is driven by clinical severity and the organ system at risk.

Amphetamine toxicity is diagnosed clinically from exposure history, toxidrome, serial vital signs, mental-status examination, and complication screening. Patients may not disclose recent methamphetamine use, and the differential diagnosis of sympathomimetic findings is broad; obtain urine toxicology as an adjunct when it will clarify exposure or competing causes, not as the sole basis for diagnosis or disposition. [7][9][21]

For moderate or severe presentations, obtain a CBC, comprehensive chemistry panel, CK, and urinalysis to identify renal dysfunction, electrolyte disturbance, and muscle injury. Add troponin for chest pain, dyspnea, concerning ECG findings, or suspected myocardial injury; BNP can assist when acute heart failure or methamphetamine-associated cardiomyopathy is suspected. [21][22]

Obtain a 12-lead ECG for cardiovascular symptoms, hemodynamic instability, marked tachycardia, or suspected co-ingestion. When clinical findings suggest ischemia or structural cardiac disease, use serial cardiac assessment and imaging directed by the presentation; amphetamine exposure has been associated with vasospasm, myocardial infarction, aortic dissection, Takotsubo cardiomyopathy, and tachyarrhythmia. [1][3][5][10][21]
- Consider blood or urine gas chromatography/mass spectrometry when definitive identification is clinically important, such as an unclear exposure with major medicolegal, diagnostic, or treatment implications. [7][9]
- Obtain chest radiography when respiratory or cardiopulmonary findings warrant it; chest x-ray is among investigations used selectively in amphetamine toxicity. [7][9]
- With injection exposure plus fever, murmur, embolic findings, or focal bone/joint symptoms, evaluate for endovascular, bloodstream, or musculoskeletal infection rather than attributing illness to intoxication. [21][22]

### Differentiate intoxication from serotonin syndrome

Amphetamine products can precipitate serotonin syndrome, particularly with concomitant serotonergic drugs or CYP2D6 inhibitors. The actionable pattern is mental-status change plus autonomic instability and neuromuscular findings such as tremor, rigidity, myoclonus, hyperreflexia, or incoordination; seizures and gastrointestinal symptoms may occur. Stop the amphetamine and concomitant serotonergic agents immediately and institute supportive symptomatic treatment when this syndrome is suspected. [5]

### Interpret exposure history by formulation and route

Ask specifically about prescribed immediate-release or extended-release products, nonmedical tablets or powders, methamphetamine, MDMA-related compounds, route of use, timing, and co-ingestants. Amphetamines may be swallowed, insufflated, smoked, or injected; extended-release pharmacokinetics should be considered during overdose management, and amphetamine products should not be converted milligram-for-milligram because salt compositions differ. [3][4][8]

*Targeted initial investigations for suspected clinically significant amphetamine toxicity. [7][9][21][22]*

| Test | Who needs it | What an abnormal result changes |
| --- | --- | --- |
| ECG | Chest pain, dyspnea, syncope, hemodynamic instability, significant tachycardia, or suspected dysrhythmia | Identifies ischemic or rhythm abnormalities requiring cardiac-directed management and monitoring. [1][3][5][7][9][21] |
| Troponin | Chest pain, ischemic ECG changes, dyspnea, or suspected myocardial injury | Supports evaluation for myocardial injury in a patient at risk for vasospasm, infarction, or cardiomyopathy. [1][3][5][21] |
| CBC and comprehensive chemistry panel | Moderate or severe toxicity, hyperthermia, seizure, prolonged agitation, or altered mental status | Detects renal dysfunction and metabolic abnormalities that affect disposition and organ-supportive management. [7][9][21] |
| CK and urinalysis | Hyperthermia, seizure, muscle symptoms, prolonged agitation, or concern for rhabdomyolysis | Identifies muscle injury and renal involvement requiring serial assessment. [1][3][5][21] |
| Urine toxicology | Uncertain exposure or broad sympathomimetic differential | Supports exposure assessment but must be interpreted with clinical findings and exposure history. [7][9][21] |

## Treat hyperthermia, neurologic toxicity, and cardiovascular injury as separate emergencies

Disposition and monitoring follow the most severe complication, not the reported dose.

Escalate care for hyperthermia, seizure, coma, persistent severe agitation, dysrhythmia, ischemic symptoms, circulatory instability, or rhabdomyolysis. Hyperthermia can occur independently of seizures and is associated with rhabdomyolysis, coagulopathy, renal failure, and death; cooling and reassessment for organ injury take priority over attempts to enhance drug elimination. [17][20]

In a patient with severe agitation, hallucinations, paranoia, or delirium, evaluate for co-ingestion, hypoglycemia, hyperthermia, trauma, infection, and neurologic disease while reducing risk to the patient and staff. Methamphetamine-related psychosis is associated with dose, duration of use, preexisting vulnerability to psychosis, and possibly sleep deprivation; persistent or atypical symptoms warrant psychiatric and medical reassessment rather than presuming a transient intoxication state. [22]

For chest pain or hemodynamic instability, manage as a potential cardiovascular emergency rather than as uncomplicated anxiety. Amphetamine toxicity can produce hypertension or hypotension, tachyarrhythmia, vasospasm, myocardial infarction, aortic dissection, Takotsubo cardiomyopathy, and circulatory collapse; ECG, biomarkers, repeated examinations, and syndrome-directed imaging should determine escalation. [1][3][5][10][21]
- Monitor renal function, electrolytes, CK, and urine findings when rhabdomyolysis is suspected; acute kidney injury is a recognized complication of severe stimulant toxicity. [17][21]
- Evaluate seizures, focal deficits, or coma for cerebrovascular complications and other structural causes because cerebral vascular accidents and coma occur in amphetamine overdose. [1][3][5]
- When managing possible mixed overdose, account for multiple drug ingestion; amphetamine toxicity may coexist with sedatives, opioids, serotonergic agents, or other stimulants. [1][3][5]

### Medication-related and interaction risks

For prescribed amphetamine products, concurrent MAOI use is contraindicated, including linezolid or intravenous methylene blue, and a 14-day interval after stopping an MAOI is required because of hypertensive-crisis risk. In suspected serotonin syndrome, stop the amphetamine and all concomitant serotonergic agents immediately. [1][4][5][6]
- Do not substitute one amphetamine product for another on a milligram-per-milligram basis during medication reconciliation or overdose estimation because amphetamine salt compositions differ. [4]
- Consider prolonged or delayed toxicity when an extended-release product is involved; product pharmacokinetics affect observation and overdose assessment. [3]

*Complication-based escalation in amphetamine toxicity. [1][3][5][17][21][22]*

| Dominant complication | Monitoring focus | Escalation trigger |
| --- | --- | --- |
| Hyperthermia | Core temperature, mental status, CK, renal function, urinalysis | Temperature >104°F, worsening mental status, seizure, or laboratory evidence of rhabdomyolysis/renal injury. [1][3][5][17][21] |
| Cardiovascular toxicity | Continuous rhythm assessment, blood pressure, ECG, cardiac biomarkers when indicated | Persistent chest pain, ischemic ECG change, dysrhythmia, syncope, shock, or concern for dissection/cardiomyopathy. [1][3][5][21] |
| Neurologic or psychiatric toxicity | Serial mental status, temperature, glucose, seizure activity, trauma screen | Seizure, coma, focal deficit, uncontrolled agitation, or persistent psychosis after immediate medical causes are assessed. [1][3][5][22] |
| Rhabdomyolysis or renal injury | CK, creatinine, electrolytes, urinalysis, urine output | Worsening renal function, electrolyte abnormality, or progressive muscle injury. [17][21] |

## Base observation and admission on complications and formulation

A reported exposure amount is less informative than trajectory, formulation, and organ injury.

Continue observation until mental status, temperature, vital signs, and cardiovascular findings show a sustained favorable trajectory and no evolving complication is identified. Extend monitoring when exposure involves an extended-release formulation, when history is unreliable, or when agitation, hyperthermia, abnormal ECG findings, elevated troponin, rising CK, renal injury, or recurrent symptoms persist. [3][7][9][21]

Admit patients requiring ongoing monitoring for hyperthermia, rhabdomyolysis, renal dysfunction, seizure, persistent delirium or psychosis, dysrhythmia, ischemic symptoms, heart failure findings, or hemodynamic instability. ICU-level care is appropriate when airway protection, active temperature control, invasive hemodynamic support, or continuous management of severe neurologic or cardiovascular complications is required. [1][3][5][17][21]

Before discharge after a nonsevere presentation, reconcile all prescribed and nonprescribed stimulants, screen for co-occurring psychiatric illness and substance use disorder, and arrange addiction-focused follow-up when nonmedical stimulant use is identified. Diagnosis of amphetamine or methamphetamine use disorder is clinical, and treatment planning should account for co-occurring psychiatric conditions and recurrent use or relapse. [7][9]
- Document route, formulation, timing, estimated dose, co-ingestants, and whether the exposure was intentional, therapeutic, accidental, or related to nonmedical use; these details change recurrence prevention and anticipated duration of toxicity. [3][4][8]
- For abrupt cessation after chronic CNS-stimulant exposure, anticipate extreme fatigue and depression; distinguish withdrawal from persistent intoxication or an emerging psychiatric disorder. [6]

*Disposition considerations after suspected amphetamine toxicity. [3][6][7][9][21]*

| Clinical trajectory | Disposition implication | Required next step |
| --- | --- | --- |
| Resolved symptoms with stable serial vital signs and no detected complication | Observation discharge may be considered | Provide exposure-specific counseling, medication reconciliation, and follow-up for substance-use or psychiatric needs. [7][9] |
| Extended-release exposure or uncertain timing | Need longer observation because pharmacokinetics may affect overdose course | Use formulation history and serial clinical reassessment rather than a single early examination. [3][4] |
| Abnormal ECG, troponin elevation, renal injury, elevated CK, hyperthermia, seizure, or persistent altered mental status | Hospital admission | Continue organ-specific monitoring and treatment. [1][3][5][17][21] |
| Extreme fatigue and depression after abrupt stimulant cessation | Assess for withdrawal and psychiatric risk | Evaluate mood symptoms and safety rather than interpreting all symptoms as ongoing intoxication. [6] |

## References
1. [PDF] Warnings: Abuse, Misuse, and Addiction. - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/011522s045lbl.pdf
2. [PDF] This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209905s003lbl.pdf
3. [PDF] highlights of prescribing information - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022063s007lbl.pdf
4. [PDF] Adzenys Labeling - FDA — www.fda.gov — https://www.fda.gov/media/142057/download
5. [PDF] DESOXYN (methamphetamine hydrochloride tablets), for oral use, CII — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/005378s032lbl.pdf
6. [PDF] Mydayis Labeling - FDA — www.fda.gov — https://www.fda.gov/media/142062/download
7. Amphetamine and methamphetamine use disorder — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/201
8. Amphetamine overdose - Symptoms, diagnosis and ... — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/341
9. Amphetamine and methamphetamine use disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/201?locale=tr
10. Myocardial Infarction after Inhalation of Methamphetamine — www.nejm.org — https://www.nejm.org/doi/abs/10.1056/NEJM199010183231617
11. Amphetamines: A Dangerous Illusion - Ovid — annals.org — https://annals.org/data/journals/aim/19448/aime197104010-00019.pdf
12. Closing the evidence gap in management of stimulant‐induced ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/add.70393
13. Amphetamine and Methamphetamine - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/9781118105955.ch1
14. Severe Rhabdomyolysis Associated with Acute Amphetamine ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2020/2816373
15. Case Report Amphetamine Abuse Related Acute Myocardial Infarction — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1155/2016/7967851
16. Cardiovascular complications among individuals with amphetamine-positive urine drug screening admitted to a tertiary care hospital in Riyadh — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1016731516000026
17. Cocaine Intoxication - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cocaine-intoxication
18. Dual intoxication with diazepam and amphetamine: This drug interaction probably potentiates myocardial ischemia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0306987707000278
19. CP 47,497 - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/cp-47-497
20. Pharmacology of Drugs Used as Stimulants - Wiley Online Library — accp1.onlinelibrary.wiley.com — https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.1918
21. Methamphetamine Toxicity(Archived) - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69ae1e551a63f1308cdc47a4
22. Methamphetamine Toxicities and Clinical Management - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11458184
23. The Diagnosis and Treatment of Stimulant-Related Emergencies - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12926754
24. [PDF] STIMULANT GUIDE - CDC — www.cdc.gov — https://www.cdc.gov/overdose-prevention/media/pdfs/2024/03/CDC-Stimulant-Guide.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.